CO2018002510A2 - Estructura peptídica que se une a factor de crecimiento endotelial vascular a construida con bucles de cistina, composiciones y procedimientos de elaboración - Google Patents
Estructura peptídica que se une a factor de crecimiento endotelial vascular a construida con bucles de cistina, composiciones y procedimientos de elaboraciónInfo
- Publication number
- CO2018002510A2 CO2018002510A2 CONC2018/0002510A CO2018002510A CO2018002510A2 CO 2018002510 A2 CO2018002510 A2 CO 2018002510A2 CO 2018002510 A CO2018002510 A CO 2018002510A CO 2018002510 A2 CO2018002510 A2 CO 2018002510A2
- Authority
- CO
- Colombia
- Prior art keywords
- cystine
- compositions
- loops
- constructed
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Biological Depolymerization Polymers (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219063P | 2015-09-15 | 2015-09-15 | |
| PCT/US2016/052012 WO2017049009A1 (en) | 2015-09-15 | 2016-09-15 | Cystine knot scaffold platform |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018002510A2 true CO2018002510A2 (es) | 2018-05-31 |
Family
ID=57068206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0002510A CO2018002510A2 (es) | 2015-09-15 | 2018-03-07 | Estructura peptídica que se une a factor de crecimiento endotelial vascular a construida con bucles de cistina, composiciones y procedimientos de elaboración |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US10428125B2 (enExample) |
| EP (1) | EP3350215B1 (enExample) |
| JP (2) | JP7166916B2 (enExample) |
| KR (1) | KR102846388B1 (enExample) |
| CN (4) | CN108026162B (enExample) |
| AR (1) | AR106032A1 (enExample) |
| AU (2) | AU2016323445B2 (enExample) |
| BR (1) | BR112018002263A2 (enExample) |
| CA (1) | CA2996006A1 (enExample) |
| CL (2) | CL2018000668A1 (enExample) |
| CO (1) | CO2018002510A2 (enExample) |
| CR (1) | CR20180169A (enExample) |
| IL (2) | IL294568A (enExample) |
| MA (1) | MA42828A (enExample) |
| MX (1) | MX2018002922A (enExample) |
| MY (1) | MY190552A (enExample) |
| PE (1) | PE20181293A1 (enExample) |
| PH (1) | PH12018500577A1 (enExample) |
| RU (1) | RU2770384C2 (enExample) |
| TW (1) | TWI799366B (enExample) |
| UA (1) | UA125505C2 (enExample) |
| WO (1) | WO2017049009A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| WO2019233605A1 (en) * | 2018-06-08 | 2019-12-12 | BioNTech SE | Compositions and methods for diagnosis and treatment of cancer |
| BR112022025227A2 (pt) | 2020-06-11 | 2023-01-03 | Genentech Inc | Conjugados, composição farmacêutica, formulação líquida, métodos para preparar um conjugado, para aumentar a estabilidade, para tratar um indivíduo, para entregar um polipeptídeo de ligação, para entregar um peptídeo curto, para entregar um agente biologicamente ativo, método para reduzir a conjugação lipídio-proteína-esqueleto e método para aumentar a atividade biológica, uso do conjugado e sistema ou kit |
| WO2025193946A2 (en) * | 2024-03-14 | 2025-09-18 | Genentech, Inc. | Peptides binding lrrc15 and uses thereof |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US918814A (en) | 1907-10-30 | 1909-04-20 | Handy Mfg Company | Funnel. |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| US5961955A (en) * | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| CA2320403A1 (en) | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| JP2003528632A (ja) | 2000-03-31 | 2003-09-30 | インスティティ・パスツール | 血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法 |
| MXPA02011808A (es) | 2000-06-01 | 2003-04-10 | Amgen Inc | Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos. |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| EP2316394B1 (en) | 2001-06-12 | 2016-11-23 | The Johns Hopkins University | Reservoir device for intraocular drug delivery |
| US7052705B2 (en) | 2001-10-03 | 2006-05-30 | Regeneron Pharmaceuticals, Inc. | Anti-angiogenic peptides |
| GB0130738D0 (en) | 2001-12-21 | 2002-02-06 | Serono Internat S A | Protein |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| DE102005002978B4 (de) | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| SI1844337T1 (sl) | 2005-01-24 | 2013-11-29 | Pepscan Systems B.V. | Povezovalne spojine, imunogene spojine in peptidomimetiki |
| US20060204548A1 (en) | 2005-03-01 | 2006-09-14 | Allergan, Inc. | Microimplants for ocular administration |
| CA2614358A1 (en) | 2005-06-29 | 2007-01-04 | Roselli, Patrizia | Agonistic and antagonistic peptide mimetics of the vegf alpha-helix binding region for use in therapy |
| US20070212703A1 (en) * | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| CN101583370A (zh) * | 2005-09-27 | 2009-11-18 | 阿穆尼克斯公司 | 蛋白质药物及其用途 |
| TW200732347A (en) | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
| US7918814B2 (en) | 2006-05-02 | 2011-04-05 | Georgia Tech Research Corporation | Method for drug delivery to ocular tissue using microneedle |
| WO2008045252A2 (en) * | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| WO2008070479A2 (en) | 2006-12-01 | 2008-06-12 | Allergan, Inc. | Method for determining optimum intraocular locations for drug delivery systems |
| CA2990445C (en) | 2007-08-21 | 2020-05-05 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| EP2604280A3 (en) | 2008-03-27 | 2013-10-16 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| US8557273B2 (en) | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
| US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| WO2010048588A2 (en) * | 2008-10-23 | 2010-04-29 | Massachusetts Institute Of Technology | Directed engagement of activating fc receptors |
| RU2550258C2 (ru) * | 2008-11-03 | 2015-05-10 | Молекьюлар Партнерс Аг | Связывающие белки, ингибирующие взаимодействия vegf-a рецептора |
| CA3045436C (en) | 2009-01-29 | 2025-10-07 | Forsight Vision4 Inc | Posterior segment drug delivery |
| US8778888B2 (en) * | 2009-11-06 | 2014-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use |
| US20110207653A1 (en) | 2009-12-21 | 2011-08-25 | Adrian Raiche | Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent |
| WO2011079232A1 (en) | 2009-12-23 | 2011-06-30 | Psivida Us, Inc. | Sustained release delivery devices |
| US8339139B2 (en) * | 2010-01-29 | 2012-12-25 | Infineon Technologies Ag | System and method for testing a circuit |
| AU2011326164B2 (en) | 2010-11-08 | 2016-05-05 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| US8865741B2 (en) * | 2011-02-18 | 2014-10-21 | Asana Biosciences, Llc | Aminoindane compounds and use thereof in treating pain |
| US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
| WO2014033184A1 (en) * | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| GB201218278D0 (en) * | 2012-10-11 | 2012-11-28 | Cyclogenix Ltd | Translocating peptide |
| WO2014063012A1 (en) * | 2012-10-19 | 2014-04-24 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugated knottin mini-proteins containing non-natural amino acids |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
-
2016
- 2016-09-14 TW TW105130077A patent/TWI799366B/zh active
- 2016-09-15 IL IL294568A patent/IL294568A/en unknown
- 2016-09-15 CN CN201680052527.6A patent/CN108026162B/zh active Active
- 2016-09-15 PE PE2018000390A patent/PE20181293A1/es unknown
- 2016-09-15 MX MX2018002922A patent/MX2018002922A/es unknown
- 2016-09-15 MY MYPI2018000374A patent/MY190552A/en unknown
- 2016-09-15 CN CN202210278625.9A patent/CN114591422B/zh active Active
- 2016-09-15 IL IL257399A patent/IL257399B/en unknown
- 2016-09-15 CR CR20180169A patent/CR20180169A/es unknown
- 2016-09-15 AU AU2016323445A patent/AU2016323445B2/en active Active
- 2016-09-15 CA CA2996006A patent/CA2996006A1/en active Pending
- 2016-09-15 US US15/267,087 patent/US10428125B2/en active Active
- 2016-09-15 CN CN202510314078.9A patent/CN120248097A/zh active Pending
- 2016-09-15 CN CN202210278014.4A patent/CN114805528A/zh active Pending
- 2016-09-15 WO PCT/US2016/052012 patent/WO2017049009A1/en not_active Ceased
- 2016-09-15 MA MA042828A patent/MA42828A/fr unknown
- 2016-09-15 JP JP2018513360A patent/JP7166916B2/ja active Active
- 2016-09-15 UA UAA201804058A patent/UA125505C2/uk unknown
- 2016-09-15 KR KR1020187010195A patent/KR102846388B1/ko active Active
- 2016-09-15 BR BR112018002263-2A patent/BR112018002263A2/en active Search and Examination
- 2016-09-15 RU RU2018113442A patent/RU2770384C2/ru active
- 2016-09-15 AR ARP160102810A patent/AR106032A1/es unknown
- 2016-09-15 EP EP16775922.4A patent/EP3350215B1/en active Active
-
2018
- 2018-03-07 CO CONC2018/0002510A patent/CO2018002510A2/es unknown
- 2018-03-13 CL CL2018000668A patent/CL2018000668A1/es unknown
- 2018-03-15 PH PH12018500577A patent/PH12018500577A1/en unknown
- 2018-04-03 US US15/944,700 patent/US10696721B2/en active Active
-
2019
- 2019-08-19 US US16/544,394 patent/US11407794B2/en active Active
- 2019-09-18 US US16/574,917 patent/US11155586B2/en active Active
- 2019-09-18 US US16/574,910 patent/US11078243B2/en active Active
-
2020
- 2020-06-29 US US16/915,387 patent/US20200325187A1/en not_active Abandoned
- 2020-07-02 CL CL2020001781A patent/CL2020001781A1/es unknown
-
2021
- 2021-06-28 AU AU2021204400A patent/AU2021204400B2/en active Active
-
2022
- 2022-06-15 JP JP2022096301A patent/JP7602514B2/ja active Active
- 2022-06-17 US US17/843,595 patent/US20230174596A1/en not_active Abandoned
-
2023
- 2023-10-30 US US18/497,741 patent/US20240247034A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004883A (es) | Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales. | |
| CO2020001872A2 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana | |
| CO2018002510A2 (es) | Estructura peptídica que se une a factor de crecimiento endotelial vascular a construida con bucles de cistina, composiciones y procedimientos de elaboración | |
| MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
| AR109625A1 (es) | Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas | |
| CL2019003211A1 (es) | Anticuerpos anti-garp-tgf-ß. | |
| AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| EA201691078A1 (ru) | Терапевтические пептиды | |
| JOP20190097A1 (ar) | الجلوبولينات المناعية واستخداماتها | |
| EA201792245A1 (ru) | Биоконъюгаты и их применения | |
| AR095611A1 (es) | Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1) | |
| CO2019006073A2 (es) | Estructura cristalina de gremlina 1 y anticuerpo inhibidor | |
| MX2016015868A (es) | Metodos y composiciones para el tratamiento de trastornos con polipeptidos de folistatina. | |
| PE20141149A1 (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| MX2025006169A (es) | Inmunoglobulinas de enlace a mmp13 | |
| AR093620A1 (es) | Anticuerpos bmp-6 | |
| BR112017001417A2 (pt) | variantes de proteína de ligação ao fator h e métodos para uso das mesmas | |
| EA201992883A1 (ru) | АНТИТЕЛА К TrkB | |
| UY36663A (es) | Anticuerpos anti-ap2 y agentes de unión al antígeno para tratar trastornos metabólicos | |
| BR112017028331A2 (pt) | proteínas de fusão que se ligam a receptores fc humanos | |
| AR095334A1 (es) | Composiciones nutricionales que contienen un componente peptídico con propiedades estimulantes de la adiponectina y método para promover un peso corporal saludable | |
| PE20170287A1 (es) | Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso | |
| MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
| CL2017003144A1 (es) | Péptidos lipidados resistentes a proteasas |